bionbt.blogg.se - Quest diagnostics locations

Quest diagnostics locations free#

Dick’s Sporting Goods Lifted By Institutional Shift.

Is Fisker Ready to Re-Emerge as the Tesla Killer?.

Chipotle is Cooking Up Another Run at $2,000.

Are These 2 Fintechs A Buy After Q2 Earnings?.

Are Ocugen or Amarin Good Penny Stocks to Buy?.

Quest diagnostics locations free#

Get a free copy of the research report on Quest Diagnostics (DGX).

The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Insiders own 1.70% of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Following the sale, the director now directly owns 23,933 shares in the company, valued at approximately $3,255,845.32. The shares were sold at an average price of $136.04, for a total transaction of $272,080.00. Ring sold 2,000 shares of the firm’s stock in a transaction on Monday, August 1st. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $148.50. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Thursday, July 7th. Morgan Stanley restated an “equal weight” rating and issued a $142.00 target price on shares of Quest Diagnostics in a report on Monday. Analysts Set New Price TargetsĭGX has been the topic of several research reports. Quest Diagnostics’s payout ratio is 21.96%.

This represents a $2.64 annualized dividend and a dividend yield of 2.03%. The ex-dividend date is Monday, October 3rd. Stockholders of record on Tuesday, October 4th will be given a dividend of $0.66 per share. The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 19th. As a group, equities analysts anticipate that Quest Diagnostics Incorporated will post 9.69 earnings per share for the current year. During the same quarter last year, the company posted $3.18 EPS. The company’s revenue was down 3.8% compared to the same quarter last year. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The business had revenue of $2.45 billion for the quarter, compared to analysts’ expectations of $2.34 billion. The medical research company reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.26 by $0.10. Quest Diagnostics ( NYSE:DGX – Get Rating) last issued its quarterly earnings results on Thursday, July 21st. Hedge funds and other institutional investors own 89.89% of the company’s stock. Profund Advisors LLC now owns 2,657 shares of the medical research company’s stock worth $460,000 after purchasing an additional 250 shares during the last quarter. Finally, Profund Advisors LLC boosted its holdings in Quest Diagnostics by 10.4% in the fourth quarter. ProShare Advisors LLC now owns 26,683 shares of the medical research company’s stock worth $4,617,000 after purchasing an additional 4,776 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Quest Diagnostics by 21.8% in the fourth quarter. Savant Capital LLC purchased a new stake in shares of Quest Diagnostics during the fourth quarter valued at approximately $260,000. Northern Trust Corp now owns 1,506,171 shares of the medical research company’s stock valued at $260,583,000 after buying an additional 38,994 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Quest Diagnostics by 2.7% during the fourth quarter. Keybank National Association OH now owns 2,611 shares of the medical research company’s stock valued at $452,000 after buying an additional 275 shares during the last quarter. Keybank National Association OH grew its holdings in shares of Quest Diagnostics by 11.8% during the fourth quarter. TD Asset Management Inc.’s holdings in Quest Diagnostics were worth $12,477,000 as of its most recent filing with the Securities & Exchange Commission.Ī number of other institutional investors have also recently made changes to their positions in DGX. The fund owned 91,168 shares of the medical research company’s stock after buying an additional 13,354 shares during the quarter. grew its position in shares of Quest Diagnostics Incorporated ( NYSE:DGX – Get Rating) by 17.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.